HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.

AuthorsNicholas J Short, Marina Konopleva, Tapan Kadia, Partow Kebriaei, Naval Daver, Xuelin Huang, Lucia Masarova, Robin Cook, Nitin Jain, Elias Jabbour, Hagop Kantarjian, Farhad Ravandi
JournalAmerican journal of hematology (Am J Hematol) Vol. 96 Issue 7 Pg. E229-E232 (07 01 2021) ISSN: 1096-8652 [Electronic] United States
PMID33780038 (Publication Type: Letter, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Bridged Bicyclo Compounds, Heterocyclic
  • Imidazoles
  • Pyridazines
  • Sulfonamides
  • ponatinib
  • venetoclax
Topics
  • Adult
  • Aged
  • Antineoplastic Agents (administration & dosage, therapeutic use)
  • Bridged Bicyclo Compounds, Heterocyclic (administration & dosage, therapeutic use)
  • Humans
  • Imidazoles (administration & dosage, therapeutic use)
  • Middle Aged
  • Neoplasm Recurrence, Local (drug therapy, genetics)
  • Philadelphia Chromosome
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy, genetics)
  • Pyridazines (administration & dosage, therapeutic use)
  • Sulfonamides (administration & dosage, therapeutic use)
  • Survival Analysis
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: